scholarly journals Update on Therapeutic Approaches for Rheumatoid Arthritis

2016 ◽  
Vol 23 (21) ◽  
pp. 2190-2203 ◽  
Author(s):  
Eugénia Nogueira ◽  
Andreia Gomes ◽  
Ana Preto ◽  
Artur Cavaco-Paulo
Life Sciences ◽  
2020 ◽  
Vol 254 ◽  
pp. 117734 ◽  
Author(s):  
Jafar Karami ◽  
Maryam Masoumi ◽  
Hossein Khorramdelazad ◽  
Hamidreza Bashiri ◽  
Parisa Darvishi ◽  
...  

2020 ◽  
Vol 89 ◽  
pp. 107064
Author(s):  
Maryam Masoumi ◽  
Mohsen Mehrabzadeh ◽  
Salman Mahmoudzehi ◽  
Mohammad Javad Mousavi ◽  
Sirous Jamalzehi ◽  
...  

2016 ◽  
Vol 79 ◽  
pp. 52-61 ◽  
Author(s):  
L. Dinesh Kumar ◽  
R. Karthik ◽  
N. Gayathri ◽  
T. Sivasudha

2013 ◽  
Vol 2013 ◽  
pp. 1-23 ◽  
Author(s):  
Carl D. Richards

Oncostatin M is a secreted cytokine involved in homeostasis and in diseases involving chronic inflammation. It is a member of the gp130 family of cytokines that have pleiotropic functions in differentiation, cell proliferation, and hematopoetic, immunologic, and inflammatory networks. However, Oncostatin M also has activities novel to mediators of this cytokine family and others and may have fundamental roles in mechanisms of inflammation in pathology. Studies have explored Oncostatin M functions in cancer, bone metabolism, liver regeneration, and conditions with chronic inflammation including rheumatoid arthritis, lung and skin inflammatory disease, atherosclerosis, and cardiovascular disease. This paper will review Oncostatin M biology in a historical fashion and focus on its unique activities, in vitro and in vivo, that differentiate it from other cytokines and inspire further study or consideration in therapeutic approaches.


2017 ◽  
Vol 7 (1) ◽  
pp. 9-14
Author(s):  
Juliana Barcellos de Souza

Neste artigo de revisão narrativa atualizam-se alguns conceitos de dor articular. A prevalência da dor articular aumenta com o avanço da idade, assim como os custos no tratamento das limitações e incapacidades. Compreender as diferenças entre dor aguda e dor crônica permite melhor abordagem das dores articulares, onde a primeira representa um sinal de alerta e a segunda é considerada uma patologia em si. As causas da cronificação da dor ainda são incertas, porém, alguns modelos são propostos e discutidos, como a sensibilização central por excesso de informação nociceptiva, seja esta de origem inflamatória, traumática ou outra. Em dores crônicas inflamatórias - como nas Artrites reumatoides – destaca-se a importância de iniciar o tratamento precoce de forma agressiva para inibir o processo inflamatório e as deformidades estruturais. Osteoartrites, embora sejam predominantemente descritas por suas alterações degenerativas nas articulações, têm atualmente reconhecida sua fase inflamatória inicial. A dor articular tende a ser abordada predominantemente sob o ponto de vista biomecânico e inflamatório, contudo, a ausência da abordagem do componente neuropática da dor crônica, nas fases iniciais, é uma das causas de elevados custos e de grandes deformidades articulares.  Finalmente aborda-se a importância do movimento e da educação do paciente com dor articular com base no modelo biopsicossocial de saúde e dor.Palavras-chave: Dor articular; Artrite reumatoide; Osteoartrite; Dor inflamatória e neuropáticaABSTRACTThis article is a joint pain update. Prevalence rates, incapacity, and social and economic burden of joint pain increase with the advancing age. Understanding differences about acute and chronic pain could improve therapeutic approaches. Negligence early treatment of acute joint pain can increase costs of treatment and joint deformities. Rheumatoid arthritis guidelines propose an aggressive initial approach of treatment with the aim to protect joint structure from inflammation and deformity. In addition to inflammatory joint pain, the neuropathic pain was also explained; central sensitization and neuropathic pain associated to joint pain. Finally, the importance of motion and education of patients with chronic pain were addressed following the pain and health biopsychosocial model. Keywords: Joint pain; Rheumatoid arthritis; Osteoarthritis; Inflammatory and neuropathic pain


2010 ◽  
Vol 10 ◽  
pp. 2248-2253 ◽  
Author(s):  
Xiao Hua Pan ◽  
Jianxin Zhang ◽  
Xiaowei Yu ◽  
Ling Qin ◽  
Ligeng Kang ◽  
...  

Due to the complex etiology of rheumatoid arthritis (RA), it is difficult to be completely cured at the current stage although many approaches have been applied in clinics, especially the wide application of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). New drug discovery and development via the recently discovered cholinergic anti-inflammatory and antinociceptive pathways should be promising. Based on the above, the nicotinic acetylcholine receptor agonists maintain the potential for the treatment of RA. Therefore, new therapeutic approaches may rise from these two newly discovered pathways. More preclinical experiments and clinical trials are required to confirm our viewpoint.


2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Céline Coppard ◽  
Francis Bonnefoy ◽  
Dalil Hannani ◽  
Françoise Gabert ◽  
Olivier Manches ◽  
...  

Abstract Background Despite major advances in rheumatoid arthritis outcome, not all patients achieve remission, and there is still an unmet need for new therapeutic approaches. This study aimed at evaluating in a pre-clinical murine model the efficacy of extracorporeal photopheresis (ECP) in the treatment of rheumatoid arthritis, and to provide a relevant study model for dissecting ECP mechanism of action in autoimmune diseases. Methods DBA/1 mice were immunized by subcutaneous injection of bovine collagen type II, in order to initiate the development of collagen-induced arthritis (CIA). Arthritic mice received 3 ECP treatments every other day, with psoralen + UVA-treated (PUVA) spleen cells obtained from arthritic mice. Arthritis score was measured, and immune cell subsets were monitored. Results ECP-treated mice recovered from arthritis as evidenced by a decreasing arthritic score over time. Significant decrease in the frequency of Th17 cells in the spleen of treated mice was observed. Interestingly, while PUVA-treated spleen cells from healthy mouse had no effect, PUVA-treated arthritic mouse derived-spleen cells were able to induce control of arthritis development. Conclusions Our results demonstrate that ECP can control arthritis in CIA-mice, and clarifies ECP mechanisms of action, showing ECP efficacy and Th17 decrease only when arthritogenic T cells are contained within the treated sample. These data represent a pre-clinical proof of concept supporting the use of ECP in the treatment of RA in Human.


Sign in / Sign up

Export Citation Format

Share Document